Literature DB >> 17289376

A time trend analysis of papillary and follicular cancers as a function of tumour size: a study of data from six cancer registries in France (1983-2000).

M Colonna1, A V Guizard, C Schvartz, M Velten, N Raverdy, F Molinie, P Delafosse, B Franc, P Grosclaude.   

Abstract

The incidence of thyroid cancers, and in particular the papillary forms, has been increasing sharply for many years in Western countries. However, the factors explaining this increase have not been clearly established. Some studies mention the effects of radioactive fallout, particularly after the accident in Chernobyl. Another probable cause is related to progress in medical practice, and particularly in diagnosis. In this article, we describe time trends in the incidence of papillary and follicular cancers, taking into account the size of the tumour at the time of diagnosis. The analysis was carried out on cases from six French cancer registries for the period 1983-2000. Anatomopathological reports concerning 3381 cancer cases were systematically recoded and centralised, following ICDO-3 rules. Over the whole period, the annual percent change of the incidence of papillary cancers was +8.13% and +8.98%, respectively in men and in women. For micropapillary carcinomas (< or = 10 mm), this increase was respectively +12.05% and +12.85%. There is no significant effect of period apart from micropapillary carcinomas in women. However, a birth cohort effect exists for some groups. This effect corresponds to an acceleration in the risk for people born after the 1930s. For the most recent period (1998-2000), half the cases of papillary cancer were micropapillary carcinomas, and for one third of these, the tumour was < or = 5 mm. Our description of a time trend of incidence as a function of tumour size supports the hypothesis of the role of medical practice in a context of high prevalence. Obviously, these findings do not exclude the possible role of other factors.

Entities:  

Mesh:

Year:  2007        PMID: 17289376     DOI: 10.1016/j.ejca.2006.11.024

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  45 in total

1.  [Benign thyroid nodule or thyroid cancer?].

Authors:  D Führer; K W Schmid
Journal:  Internist (Berl)       Date:  2010-05       Impact factor: 0.743

2.  The Akt-specific inhibitor MK2206 selectively inhibits thyroid cancer cells harboring mutations that can activate the PI3K/Akt pathway.

Authors:  Ruixin Liu; Dingxie Liu; Eliana Trink; Ermal Bojdani; Guang Ning; Mingzhao Xing
Journal:  J Clin Endocrinol Metab       Date:  2011-02-02       Impact factor: 5.958

3.  Explaining the increasing incidence of differentiated thyroid cancer.

Authors:  Jacques How; Roger Tabah
Journal:  CMAJ       Date:  2007-11-20       Impact factor: 8.262

4.  Thyroid cancer incidence among active duty U.S. military personnel, 1990-2004.

Authors:  Lindsey R Enewold; Jing Zhou; Susan S Devesa; Amy Berrington de Gonzalez; William F Anderson; Shelia H Zahm; Alexander Stojadinovic; George E Peoples; Aizenhawar J Marrogi; John F Potter; Katherine A McGlynn; Kangmin Zhu
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-09-13       Impact factor: 4.254

5.  Causes of referral to the first endocrine visit of patients with thyroid carcinoma in a mildly iodine-deficient area.

Authors:  Michela Marina; Gian Paolo Ceda; Raffaella Aldigeri; Graziano Ceresini
Journal:  Endocrine       Date:  2016-10-14       Impact factor: 3.633

Review 6.  The role of nuclear medicine in differentiated thyroid cancer.

Authors:  Susanne Kohlfürst
Journal:  Wien Med Wochenschr       Date:  2012-07-20

7.  Current management of papillary thyroid microcarcinoma in Canada.

Authors:  Mazin Merdad; Antoine Eskander; John De Almeida; Jeremy Freeman; Lorne Rotstein; Shereen Ezzat; Anna M Sawka; David P Goldstein
Journal:  J Otolaryngol Head Neck Surg       Date:  2014-08-14

8.  Changing patterns in thyroid cancer incidence and mortality in the Slovak Republic by histological type and age.

Authors:  Martina Ondrusova; Karol Kajo; Dalibor Ondrus
Journal:  Int J Clin Oncol       Date:  2013-11-09       Impact factor: 3.402

9.  Rising incidence of thyroid cancer in Singapore not solely due to micropapillary subtype.

Authors:  J H Shulin; J Aizhen; S M Kuo; W B Tan; K Y Ngiam; R Parameswaran
Journal:  Ann R Coll Surg Engl       Date:  2018-03-15       Impact factor: 1.891

10.  Axitinib: The evidence of its potential in the treatment of advanced thyroid cancer.

Authors:  Hari A Deshpande; Scott Gettinger; Julie Ann Sosa
Journal:  Core Evid       Date:  2010-06-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.